نتایج جستجو برای: hiv 1 dna vaccine

تعداد نتایج: 3346593  

Journal: :Clinical and vaccine immunology : CVI 2008
Cara C Wilson Mark J Newman Brian D Livingston Samantha MaWhinney Jeri E Forster Jim Scott Robert T Schooley Constance A Benson

A DNA vaccine encoding sequence-conserved human immunodeficiency virus type 1 (HIV-1)-derived cytotoxic T-lymphocyte (CTL) epitopes from multiple HIV-1 gene products (designated EP HIV-1090) was evaluated in a placebo-controlled, dose escalation phase 1 clinical trial of HIV-1-infected subjects receiving potent combination antiretroviral therapy. Patients received four intramuscular immunizatio...

Journal: :Journal of virology 2008
Kara S Cox James H Clair Michael T Prokop Kara J Sykes Sheri A Dubey John W Shiver Michael N Robertson Danilo R Casimiro

Results from Merck's phase II adenovirus type 5 (Ad5) gag/pol/nef test-of-concept trial showed that the vaccine lacked efficacy against human immunodeficiency virus (HIV) infection in a high-risk population. Among the many questions to be explored following this outcome are whether (i) the Ad5 vaccine induced the quality of T-cell responses necessary for efficacy and (ii) the lack of efficacy i...

2012
Paula Ordonhez Rigato Milton Maciel Adriana Letícia Goldoni Orlando Guerra Piubelli Noemia Mie Orii Ernesto Torres Marques Joseph Thomas August Alberto José da Silva Duarte Maria Notomi Sato

Infants born to HIV-infected mothers are at high risk of becoming infected during gestation or the breastfeeding period. A search is thus warranted for vaccine formulations that will prevent mother-to-child HIV transmission. The LAMP/gag DNA chimeric vaccine encodes the HIV-1 p55gag fused to the lysosome-associated membrane protein-1 (LAMP-1) and has been shown to enhance anti-Gag antibody (Ab)...

Journal: :The Journal of infectious diseases 1994
J R Mascola J Louwagie F E McCutchan C L Fischer P A Hegerich K F Wagner A K Fowler J G McNeil D S Burke

At least five distinct genetic subtypes (genotypes) of human immunodeficiency virus type 1 (HIV-1) have been identified by DNA sequencing. Current vaccine candidates are based on virus strains from North America and Europe that represent only one subtype. The extent to which distinct genotypes of HIV-1 correspond to antigenically distinguishable serotypes is largely unknown and may be criticall...

2009

Objective 1: Define the safety and efficacy of the multiclade DNA prime/rAd5 boost VRC candidate HIV-1 vaccine. Objective 2: Define immunological correlates of vaccine-induced protection from HIV-1 acquisition and/or disease progression to advance development of an HIV-1 candidate Objective 1: Determine the structure of a trimeric HIV-1 Envelope spike and delineate how oligomerization influence...

2014
Yuxin Chen Shixia Wang Shan Lu

DNA vaccination has been studied in the last 20 years for HIV vaccine research. Significant experience has been accumulated in vector design, antigen optimization, delivery approaches and the use of DNA immunization as part of a prime-boost HIV vaccination strategy. Key historical data and future outlook are presented. With better understanding on the potential of DNA immunization and recent pr...

2015
Agricola Joachim Charlotta Nilsson Said Aboud Muhammad Bakari Eligius F. Lyamuya Merlin L. Robb Mary A. Marovich Patricia Earl Bernard Moss Christina Ochsenbauer Britta Wahren Fred Mhalu Eric Sandström Gunnel Biberfeld Guido Ferrari Victoria R. Polonis

UNLABELLED Vaccine-induced HIV antibodies were evaluated in serum samples collected from healthy Tanzanian volunteers participating in a phase I/II placebo-controlled double blind trial using multi-clade, multigene HIV-DNA priming and recombinant modified vaccinia Ankara (HIV-MVA) virus boosting (HIVIS03). The HIV-DNA vaccine contained plasmids expressing HIV-1 gp160 subtypes A, B, C, Rev B, Ga...

Journal: :AIDS research and human retroviruses 2004
Binshan Shi Sean M Philpott Barbara Weiser Carla Kuiken Cheryl Brunner Guowei Fang Keith R Fowke Francis A Plummer Sarah Rowland-Jones Job Bwayo Aggrey O Anzala Joshua Kimani Rupert Kaul Harold Burger

The majority of HIV-1 infections worldwide occur in Africa, where subtype B viruses are rare and intersubtype recombinants are common. Pathogenesis and vaccine studies need to focus on viruses derived from African patients, and infectious HIV-1 molecular clones can be useful tools. To clone non-B subtypes and recombinant viruses from patients, we cultivated HIV-1 from the plasma of a Kenyan lon...

2012
Rafael Ribeiro Almeida Daniela Santoro Rosa Susan Pereira Ribeiro Vinicius Canato Santana Esper Georges Kallás John Sidney Alessandro Sette Jorge Kalil Edecio Cunha-Neto

T-cell based vaccine approaches have emerged to counteract HIV-1/AIDS. Broad, polyfunctional and cytotoxic CD4(+) T-cell responses have been associated with control of HIV-1 replication, which supports the inclusion of CD4(+) T-cell epitopes in vaccines. A successful HIV-1 vaccine should also be designed to overcome viral genetic diversity and be able to confer immunity in a high proportion of ...

2015
Nicola J Borthwick Maximillian Rosario Torben Schiffner Emma Bowles Tina Ahmed Peter Liljeström Guillaume E Stewart-Jones Jan W Drijfhout Cornelis J M Melief Tomáš Hanke

Vaccines delivering T cell immunogen HIVconsv vectored by plasmid DNA, non-replicating simian adenovirus and non-replicating modified vaccinia virus Ankara (MVA) are under clinical evaluation in phase I/IIa trials in UK, Europe, and Africa. While these vaccines aim to induce effector T cell responses specific for HIV-1, we here characterized the humoral responses induced by HIVconsv administrat...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید